Generic substitution of antiepileptic drugs: What's a clinician to do?

Neurology: Clinical Practice

Volumn 3, Issue 2, 2013, Pages 161-164

  Privitera, Michael ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EMERGENCY CARE; EPILEPSY; EPILEPTIC STATE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HEART ARRHYTHMIA; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEDICAL INFORMATION; NEGATIVE SYNDROME; PHARMACY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

EID: 84880093360     PISSN: 21630402     EISSN: 21630933     Source Type: Journal    
DOI: 10.1212/CPJ.0b013e31828d9fc9     Document Type: Article

References (11)

1. Savings with generic drugs. Available at: http://www.fda.gov/cder/ogd/02- 10-BCBS-gjb/sld003.htm. Accessed March 31, 2008.
2. Henney JE. From the food and drug administration. JAMA 1999;282:1995.
3. US Senate, Committee on Appropriations. Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bill, 2010. Report 111-39. Text from: Committee Reports. Available at: LexisNexis Congressional. http://thomas.loc.gov/cgi-bin/cpquery/?&sid=cp111ds5Bg&r- n=sr039.111&hd-count=50&item=39&sel=DOC&. Accessed July 3, 2009.
4. Definition of bioequivalence. Available at: http://www.fda.gov/cder/ogd/ 02-10-BCBS-gjb/sld028.htm. Accessed March 31, 2008.
5. Davit BA, Nwakama PE, Buehler GJ, et al. A review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009;43;1583-1597.
6. Privitera M. Generic antiepileptic drugs: current controversies and future directions. Epilepsy Curr 2008;8:113-117.
7. Davit BM, Chen ML, Conner DP, et al. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration. AAPS J 2012;14:915-924.
8. Andermann F, Duh MS, Gosselin A. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007;28:464-469.
9. ZachryWMIII, DoanQD, Clewell JD, Smith BJ. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug product changes. Epilepsia 2009;50:493-500.
10. Devine ST, Weisbart E, Barron J, Behm A. Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugs. Curr Med Res Opin 2010;26:455-463.
11. Krauss GL, Caffo B, Chang Y-T, et al. Assessing bioequivalence of generic anti-epilepsy drugs. Ann Neurol 2011;70:221-228.